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Summary
Mutations of the rearranged during transfection (RET) proto-oncogene, located on chromosome 10q11.2, cause multiple 
endocrine neoplasia type 2A (MEN2A). Patients with mutations at the codon 609 usually exhibit a high penetrance of 
medullary thyroid cancer (MTC), but a sufficiently low penetrance of phaeochromocytoma that screening for this latter 
complication has been called to question. Patients with other RET mutations are at higher risk of younger age onset 
phaeochromocytoma if they also possess other RET polymorphisms (L769L, S836S, G691S and S904S), but there are no 
similar data for patients with 609 mutations. We investigated the unusual phenotypic presentation in a family with 
MEN2A due to a C609Y mutation in RET. Sanger sequencing of the entire RET-coding region and exon–intron boundaries 
was performed. Five family members were C609Y mutation positive: 3/5 initially presented with phaeochromocytoma, 
but only 1/5 had MTC. The index case aged 73 years had no evidence of MTC, but presented with phaeochromocytoma. 
Family members also possessed the G691S and S904S RET polymorphisms. We illustrate a high penetrance of 
phaeochromocytoma and low penetrance of MTC in patients with a RET C609Y mutation and polymorphisms G691S 
and S904S. These data highlight the need for life-long screening for the complications of MEN2A in these patients and 
support the role for the screening of RET polymorphisms for the purposes of risk stratification.
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Learning points:
•	 C609Y RET mutations may be associated with a life-long risk of phaeochromocytoma indicating the importance of 
life-long screening for this condition in patients with MEN2A.
•	 C609Y RET mutations may be associated with a lower risk of MTC than often quoted, questioning the need for 
early prophylactic thyroid surgery discussion at the age of 5 years.
•	 There may be a role for the routine screening of RET polymorphisms, and this is greatly facilitated by the increasing 
ease of access to next-generation sequencing.
Background
Multiple endocrine neoplasia type 2A (MEN2A) is an 
autosomal dominant syndrome caused by mutations 
in the rearranged during transfection (RET) proto-
oncogene located on chromosome 10q11.21 (http://
www.omim.org/entry/164761, 27.7.2016). Those 
affected have a predisposition to develop medullary 
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thyroid cancer (MTC), phaeochromocytoma and 
hyperparathyroidism. Mutations in numerous codons 
of the RET proto-oncogene are associated with the 
development of MEN2A. The penetrance of MTC and 
phaeochromocytoma varies according to which codon 
carries the mutation and, more specifically, by the 
different amino acid substitutions at each codon (1). 
There are further data to suggest that possession of two 
or more RET polymorphisms L769L, S836S, G691S and 
S904S in those with some RET disease-associated codon 
mutations can increase the likelihood of developing 
phaeochromocytoma, with presentation at a younger 
age (2), but there are no such data for those with 
mutations at codon 609. Moreover, there are conflicting 
data as to the penetrance of phaeochromocytoma in 
patients with codon 609 mutations (3), and it has even 
been questioned whether there is a need to screen 
for phaeochromocytoma in these patients (1). Here, 
our objective was to investigate an unusually high 
penetrance of phaeochromocytoma and low penetrance 
of MTC across three generations in a family with the 
C609Y mutation (Figure 1).
Case presentation
Case 1
A 73-year-old Caucasian female presented to our 
institution in 2009 with a history of recurrent dizziness 
and shaking over several years.
Case 2
Case 1’s son, a 54-year-old man, had a left-sided 
phaeochromocytoma in 1988 aged 27 (before genetic 
testing was available) and underwent an adrenalectomy 
at that time at another institution.
Case 3
Case 3 is the daughter of Case 2, and hence, granddaughter 
of Case 1. She was admitted to hospital in 2008, aged 
25, after a 2-year history of worsening abdominal pain, 
headaches and weight loss.
Case 4
Case 4 is the daughter of Case 1, and sister of Case 2. After 
the positive test for the C609Y mutation in her mother 
and brother, she tested positive for this mutation in 2009, 
aged 50 years.
Case 5
Case 5 is the son of Case 2 and brother of Case 3. In 2009, 
aged 23 years, after detection of the C609Y RET mutation 
in his grandmother and father, this patient was found to 
carry the same mutation.
Investigation
Case 1
Blood pressure was 140/67 mmHg. 24-h urinary 
metadrenaline was 2326–3249 nmol/24 h (0–2000). MRI 
revealed a heterogenous right adrenal lesion 2.5 cm in 
diameter, with high signal on T2 sequences, and which 
showed uptake on MIBG scintigraphy, confirming a 
diagnosis of phaeochromocytoma. Basal parathyroid 
hormone and calcitonin were modestly raised at 
11.1 pmol/L (1.5–6.9) and 30.1 ng/L (0–5.5) respectively, 
with adjusted serum calcium just above normal 
range at 2.7 mmol/L (2.20–2.60). Ultrasound of the thyroid 
found suspicious lesions bilaterally. However, fine needle 
aspiration biopsies confirmed these to be benign nodules.
Case 2
After the diagnosis of phaeochromocytoma in his 
mother in 2009, Case 2 underwent genetic testing, 
which showed that he had the C609Y mutation in the 
RET proto-oncogene. Plasma calcitonin rose from a basal 
Figure 1
Family tree depicting penetrance of MEN2A.
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value of 4.5 ng/L to a peak value of 90.9 ng/L (0–18.9) after 
pentagastrin stimulation. 24-h urinary metanephrines/
normetanephrines and serum calcium were normal.
Case 3
The patient was hypertensive with elevated 24-h 
urine normetadrenaline of 19 703 mmol (0–4900) and 
metadrenaline of 8395 mmol (0–2000). MRI revealed 
a right-sided adrenal mass of 6 × 4 cm consistent with 
phaeochromocytoma. Plasma calcitonin and serum 
calcium were normal.
Case 4
Phenotypic screening tests revealed an elevated 
basal calcitonin of 22.5 ng/L, which rose to >200 ng/L 
after pentagastrin stimulation. 24-h urinary 
metanephrines/normetanephrines and serum calcium 
were normal.
Case 5
Screening revealed an elevated plasma calcitonin of 
28 ng/L with a pentagastrin-stimulated calcitonin level 
of 280 ng/L. A small nodule was seen on ultrasound, 
and fine needle aspiration was consistent with a Thy5 
lesion suggesting MTC. 24-h urinary metanephrines/
normetanephrines and serum calcium were normal.
Treatment
Case 1
The patient was stabilised on oral phenoxybenzamine 
therapy and a right adrenalectomy was performed.
Case 2
After discussion, he elected to have a total thyroidectomy 
in 2010.
Case 3
After alpha blockade, she underwent a laparoscopic right-
sided adrenalectomy.
Case 4
There was no clear radiological evidence of MTC; however, 
she underwent a total thyroidectomy with central node 
dissection in 2010.
Case 5
The patient underwent a total thyroidectomy with central 
and left selective node dissection at levels two to five.
Outcome and follow-up
Case 1
Adrenalectomy histology showing a phaeo-
chromocytoma. A family history revealed a son and 
granddaughter with a history of phaeochromocytoma, 
and genetic analysis revealed a C609Y mutation in the 
RET proto-oncogene. Subsequent blood tests revealed 
that basal parathyroid hormone, calcitonin and calcium 
levels had returned to normal without intervention. 
A further pentagastrin stimulation test was performed 
with plasma calcitonin rising from a basal value of 
<4.0 ng/L to peak value of 12.7 ng/L (0–18.9), a normal 
response. The option of thyroid surgery was discussed 
with the patient, but she elected for non-surgical 
follow-up. Since then, fasting plasma calcitonin and 
serum calcium levels remain in the normal range, and 
there has been no evidence of recurrence or new onset 
of phaeochromocytoma, after six years of follow-up 
to date.
Case 2
Thyroidectomy histology revealed C cell hyperplasia in 
the right lobe, with no evidence of MTC. There has been 
no evidence of MTC or recurrence of phaeochromocytoma 
after 6 and 27 years of follow-up respectively.
Case 3
Histology revealed a phaeochromocytoma. Plasma 
calcitonin, serum calcium and PTH were normal. The 
patient tested negative for succinate dehydrogenase 
mutations (SDHx), but RET mutational analysis was 
not undertaken until the following year, after the 
presentation of her grandmother. The patient tested 
positive for the same C609Y mutation found in other 
members of the family. Basal calcitonin was <4.0 ng/L 
(normal 0–5.5) in 2009. Despite this, and after careful 
discussion, the patient elected for a prophylactic 
thyroidectomy in 2010, aged 27. Histology showed 
normal thyroid with no C cell hyperplasia or MTC. There 
is no evidence of MTC, recurrent phaeochromocytoma 
or hyperparathyroidism after six years of follow-up 
to date.
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Case 4
Histology revealed C cell hyperplasia but no MTC, with 
no lymph node involvement. There was an incidental 
finding of a 1mm focus of papillary microcarcinoma. 
Plasma calcitonin levels have remained undetectable 
during six years of follow-up to date, and there has been 
no evidence of phaeochromocytoma during this period 
of follow-up. To date, her children have not consented to 
genetic testing.
Case 5
Histology revealed a 0.5 mm focus of MTC in the right 
lobe with no nodal metastases. Plasma calcitonin levels 
were <4 ng/L on post-surgery pentagastrin stimulation 
tests, confirming biochemical cure of the patient’s MTC, 
and he remains so after six years of follow-up. All plasma 
metanephrine testing and adrenal imaging have been 
negative.
The unusual history of prevalent phaeochromocytoma 
and lack of clinically significant MTC in our kindred 
prompted us to look for disease-modifying factors. Of the 
RET polymorphisms L769L, S836S, G691S and S904S, we 
identified G691S and S904S in this family.
Discussion
The RET proto-oncogene encodes for a transmembrane 
tyrosine kinase receptor and germline mutations are 
disease-causing in MEN2A (4), with different mutations 
having a strong genotype–phenotype correlation (3, 5).
Our kindred carry a mutation in codon 609 with a 
change from amino acid cysteine to tyrosine (C609Y). 
What is remarkable is that three members had an initial 
presentation with a phaeochromocytoma at ages 73 
(Case 1), 27 (Case 2) and 25 (Case 3). These patients span 
three generations, and with each successive generation, 
there has been presentation with phaeochromocytoma at 
an earlier age. What is also remarkable is the low rate of 
MTC in this kindred (Table 1). It appears that C cells in the 
thyroid are more susceptible to RET activation than the 
chromaffin cells found in the adrenal medulla (6). It has 
been suggested that all individuals with MEN2A will develop 
MTC, with one-third developing phaeochromocytoma 
and one-third developing hyperparathyroidism (1). 
Although the penetrance of phaeochromocytoma and 
hyperparathyroidism is documented to be variable, there 
is general agreement that MTC is fully penetrant (3). Our 
kindred appear to have a less-aggressive thyroid phenotype 
and members of this family appear to have come to 
no harm by not having thyroidectomy at a young age. 
Within our kindred, four out of five of those affected with 
the C609Y mutation had thyroidectomies: at 27 years of 
age, Case 3 had a normal thyroid on histology; Cases 2 
and 4, aged 49 and 51 respectively, had C cell hyperplasia 
at the time of thyroidectomy. Cases 2, 3 and 4 comply 
with current thoughts on the development of MTC with 
progressive changes over time from normal thyroid to C 
cell hyperplasia before progression to MTC (7). However, 
at the age of 78, Case 1 has no biochemical evidence of 
C cell hyperplasia or MTC, but her grandson, Case 5, was 
24 when thyroid histology revealed MTC. This family 
shows a lower penetrance of MTC than current literature 
suggests, and there is variation within the family over 
time of progression to MTC.
The differences in phenotype of our kindred compared 
to others with the C609Y gene mutation prompted us 
to look for other modifying factors. We found G691S 
and S904S RET polymorphisms that have been shown 
to be associated with an increased risk of developing 
phaeochromocytoma and a lower age of presentation in 
patients with other disease-causing mutations (2). We are 
not aware of any previous data of these polymorphisms 
and mutations at codon 609, but our data suggest that 
such modifiers may be exerting an influence over the 
presentation of disease in this family, with a high rate of 
phaeochromocytoma and low rate of MTC. The American 
Table 1 Adrenal and thyroid management of RET C609Y kindred with MEN2a.
 Adrenal surgery Adrenal pathology Thyroid surgery Thyroid pathology
Case 1 Right adrenalectomy Phaeochromocytoma (age 73) None N/A
Case 2 Left adrenalectomy Phaeochromocytoma (age 27) Thyroidectomy C cell hyperplasia (aged 49)
Case 3 Right adrenalectomy Phaeochromocytoma (age 25) Thyroidectomy Normal (aged 27)
Case 4 None N/A Thyroidectomy and central node 
dissection
C cell hyperplasia (aged 51)
Case 5 None N/A Thyroidectomy and central node 
dissection
MTC (aged 24)
MTC, medullary thyroid cancer; N/A, not applicable.
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Thyroid Association (ATA) and 2014 British Thyroid 
Association Guidelines for the Management of Thyroid 
Cancer suggest prophylactic thyroid surgery at the age of 
5 be discussed with the parents of patients with moderate-
risk mutations (ATA-MOD), including those with ∆609 
mutations (8, 9). It is recommended that surgery may be 
delayed beyond 5 years of age if the following criteria are 
met: normal serum calcitonin, normal neck ultrasound, a 
less aggressive MTC family history and family preference 
(8). Due to such a low rate of MTC in our kindred, it is 
possible that other kindreds harbouring this mutation 
might not need early thyroid surgery and that the 
polymorphisms identified here in association with C609Y 
might be contributing to a protective phenotype for the 
development of MTC.
For those with 609 mutations, screening for 
phaeochromocytoma should commence at the age 
of 16 according to the ATA guidelines and at the age 
of 8 according to the European guidelines (8, 10). 
The youngest member of our kindred to present with 
phaeochromocytoma was 25  years of age. Nevertheless, 
the presentation of phaeochromocytoma in Case 1 at age 
73 emphasises the need for life-long surveillance in MEN2A 
families with this mutation. In contrast, Calva  et  al. 
screened 83 patients with the C609Y mutation and 
found no evidence of phaeochromocytoma, concluding 
that patients with this mutation may not need to be 
screened for this complication (1). Our data differ from 
these recommendations, and as phaeochromocytoma is 
a potentially life-threatening condition, we highlight the 
importance of life-long screening for this condition in 
patients with MEN2A.
In summary, C609Y RET mutations may be associated 
with a life-long risk of phaeochromocytoma and a lower 
risk of MTC than often quoted. There may be a role for 
the routine screening of RET polymorphisms, and this is 
greatly facilitated by the increasing ease of access to next-
generation sequencing.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This research did not receive any specific grant from any funding agency in 
the public, commercial or not-for-profit sector.
Patient consent
Written, informed consent has been received from the patients.
Author contribution statement
Rowena Speak wrote the case series and performed literature review. 
Dr  Jackie Cook performed genetic analysis and co-wrote the report. 
Mr Barney Harrison performed endocrine surgery (thyroid and adrenal) on 
patients and co-wrote the report. Prof John Newell-Price is the physician 
responsible for the patients and designed and co-wrote the report. 
Acknowledgements
The authors would like to thank the family members and the staff on the 
Endocrine Unit at the Royal Hallamshire Hospital in Sheffield.
References
 1 Calva D, O’Dorisio TM, Sue O’Dorisio M, Lal G, Sugg S, Weigel RJ 
& Howe JR 2009 When is prophylactic thyroidectomy indicated 
for patients with the RET codon 609 mutation? Annals of Surgical 
Oncology 16 2237–2244. (doi:10.1245/s10434-009-0524-3)
 2 Siqueira DR, Ceolin L, Ferreira CV, Romitti M, Maia SC, Maciel LM 
& Maia AL 2014 Role of RET genetic variants in MEN2-associated 
phaeochromocytoma. European Journal of Endocrinology 170 821–828. 
(doi:10.1530/EJE-14-0084)
 3 Mian C, Sartorato P, Barollo S, Zane M & Opocher G 2012 RET codon 
609 mutations: a contribution for better clinical managing. Clinics 67 
(Supplement 1) 33–36. (doi:10.6061/clinics/2012(Sup01)07)
 4 Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, 
Love DR, Mole SE, Moore JK, Papi L, et al. 1993 Germ-line mutations 
of the RET proto-oncogene in multiple endocrine neoplasia type 2A. 
Nature 363 458–460. (doi:10.1038/363458a0)
 5 Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, 
Sherman SI, Gagel RF, Lee JE & Evans DB 2003 Multiple endocrine 
neoplasia type 2: evaluation of the genotype-phenotype relationship. 
Archives of Surgery 138 409–416; discussion 416. (doi:10.1001/
archsurg.138.4.409)
 6 Jhiang SM 2000 The RET proto-oncogene in human cancers. Oncogene 
19 5590–5597. (doi:10.1038/sj.onc.1203857)
 7 Machens A, Lorenz K, Sekulla C, Hoppner W, Frank-Raue K, Raue F 
& Dralle H 2013 Molecular epidemiology of multiple endocrine 
neoplasia 2: implications for RET screening in the new millenium. 
European Journal of Endocrinology 168 307–314. (doi:10.1530/EJE-12-
0919)
 8 Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, 
Machens A, Moley JF, Pacini F, et al. 2015 Revised american thyroid 
association guidelines for the management of medullary thyroid 
carcinoma. Thyroid 25 567–610. (doi:10.1089/thy.2014.0335)
 9 Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, 
Gilbert J, Harrison B, Johnson SJ, Giles TE, et al. 2014 Guidelines 
for the management of thyroid cancer. Clinical Endocrinology 81 
(Supplement 1) 1–122. (doi:10.1111/cen.12515)
 10 Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V 
& Williams GR 2013 2012 European thyroid association 
guidelines for genetic testing and its clinical consequences in 
medullary thyroid cancer. European Thyroid Journal 1 216–231. 
(doi:10.1159/000346174)
Received in final form 28 October 2016
Accepted 7 November 2016
